Expertise in
5
conditions

Dr. Michael S. Eggert

Sentara Medical Group
Norfolk, VA
Expertise in
5
conditions
Specialties:Intensive Care Medicine | Pulmonary Medicine
Accepting New Patients
Expertise in
5
conditions
OverviewInsuranceLocationsClinical Research

Overview

Michael Eggert is an Intensive Care Medicine specialist and a Pulmonary Medicine provider in Norfolk, Virginia. Dr. Eggert is highly rated in 5 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Interstitial Lung Disease, and Acute Interstitial Pneumonia. Dr. Eggert is currently accepting new patients.

His clinical research consists of co-authoring 8 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Intensive Care Medicine
Pulmonary Medicine
Licenses
Internal Medicine in VA
Hospital Affiliations
Sentara Norfolk General Hospital
Sentara Leigh Hospital
Sentara Careplex Hospital
Sentara Obici Hospital
Sentara Princess Anne Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana
  •  Piedmont

Locations

SENTARA MEDICAL GROUP
844 Kempsville Rd, Suite 212, Norfolk, VA 23502
757-261-5977

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
An Open-label, Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects With Pulmonary Arterial Hypertension Currently Using Tyvaso
Enrollment Status: Completed
Publish Date: November 01, 2024
Intervention Type: Drug
Study Drug: Treprostinil Inhalation Powder
Study Phase: Phase 1
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: February 06, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease
Enrollment Status: Completed
Publish Date: July 27, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Enrollment Status: Completed
Publish Date: June 02, 2022
Intervention Type: Drug
Study Drug: UT-15C
Study Phase: Phase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects With Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrollment Status: Completed
Publish Date: February 13, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

8 Total Publications

Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.
Erratum: Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.
Journal: Pulmonary circulation
Published: October 26, 2022
Similar Doctors
Expertise in
34
conditions
Dr. Carlos A. Silva
Pulmonary Medicine | Intensive Care Medicine
Expertise in
34
conditions
Dr. Carlos A. Silva
Pulmonary Medicine | Intensive Care Medicine
516 Innovation Dr, Suite 201, 
Chesapeake, VA 
 (8.2 mi)
757-524-5277
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carlos Silva is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Chesapeake, Virginia. Dr. Silva is highly rated in 34 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, and Lung Nodules. Dr. Silva is currently accepting new patients.

Expertise in
24
conditions
Dr. Alan B. Goldberg
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
24
conditions
Dr. Alan B. Goldberg
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

Sentara Medical Group

4000 Coliseum Dr, Suite 340, 
Hampton, VA 
 (18.0 mi)
757-827-2230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alan Goldberg is a Pulmonary Medicine specialist and a Sleep Medicine provider in Hampton, Virginia. Dr. Goldberg is highly rated in 24 conditions, according to our data. His top areas of expertise are Asbestosis, Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), and Obstructive Sleep Apnea. Dr. Goldberg is currently accepting new patients.

Expertise in
24
conditions
Dr. Vasantha V. Hathwar
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
24
conditions
Dr. Vasantha V. Hathwar
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine

Bayview Physician Services PC

6025 Providence Rd, 
Virginia Beach, VA 
 (2.8 mi)
757-474-7447
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vasantha Hathwar is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Virginia Beach, Virginia. Dr. Hathwar is highly rated in 24 conditions, according to our data. His top areas of expertise are Lung Metastases, Pulmonary Fibrosis, Pneumonia, Advanced Bronchoscopy, and Endoscopy. Dr. Hathwar is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile